"We are actually pleased
mantle cell and diffuse large B-cell lymphomas join in with multiple myeloma
upon the list of cancers for which SNS01-T is granted orphan-drug condition
through FDA," said Leslie J. Browne, Ph.D., Senesco's Chief Executive
Officer.
"SNS01-T
was created to selectively trigger cell dying in B-cell malignancies. Finding
orphan-drug status all these cancers are complemented from the efficacy of
SNS01-T in mouse models of MCL and DLBCL in addition to our plans to consider
the overall impact of SNS01-T in affected individuals with these cancers."
The
United States Orphan Drug Act of 1983 was made to present the introduction of brand
new drug therapies concerning the remedy for diseases that affect less than
200,000 individuals in the US.